Search Clinical Trials in the European Union

>2 years
Visits
Phase
Intake methods
Benefits
Drugs
Locations
Clinical Specialty
1581-1600 of 1,743 trials

Immunotherapy for MSI/dMMR Tumors: Pembrolizumab Study

We are studying the effects of pembrolizumab in patients with untreated localized MSI/dMMR tumors or EBV+ gastric cancer. The goal is to see if this treatment improves outcomes before and after surgery.

MSI/dMMR Tumors and EBV+ Gastric Cancer>2 yearsEfficacy phase (II)No PlaceboStandard MedicinesOncology

ABO-101 for Primary Hyperoxaluria Type 1

We are testing a new treatment, ABO-101, to see if it is safe and well-tolerated in people with Primary Hyperoxaluria Type 1. The study will also explore how the body reacts to the treatment.

Primary Hyperoxaluria>2 yearsSafety phase (I)Efficacy phase (II)No PlaceboInvestigational MedicinesPartially RemoteEndocrinologyNephrology

Lung Cancer: RMC-6236 vs. Docetaxel

We are studying a new treatment for patients with advanced lung cancer who have RAS mutations. The goal is to see if RMC-6236 works better than the standard treatment, docetaxel.

Non-Small Cell Lung Cancer>2 yearsConfirmation phase (III)No PlaceboInvestigational MedicinesCost ReimbursementOncology

Alcohol Dependence: CBD and Naltrexone Study

We are investigating whether adding Cannabidiol to Naltrexone helps reduce alcohol cravings in people with alcohol dependence. The study also looks at its effects on mood, anxiety, and overall quality of life.

Alcohol Dependence>2 yearsEfficacy phase (II)6-10 visitsInvestigational MedicinesPartially RemotePsychiatry

EGFR-Mutated Lung Cancer: ERIS Study

We are exploring the best sequence of EGFR-inhibitors for patients with EGFR-mutated lung cancer. The study also examines treatment effects, side effects, and quality of life.

EGFR-Mutated Non-Small Cell Lung Cancer>2 yearsConfirmation phase (III)6-10 visitsNo PlaceboStandard MedicinesOncology

Heart Attack Treatment: Evolocumab vs. Standard Care

We are studying whether the medication evolocumab can better prevent heart-related problems compared to standard treatments for patients who have recently had a heart attack. This trial focuses on improving cholesterol control and reducing hospitalizations.

Heart Attack>2 yearsMonitoring phase (IV)6-10 visitsPost-Trial Drug AccessNo PlaceboStandard MedicinesPartially RemoteCardiologyInternal Medicine

Plozasiran for Severe Hypertriglyceridemia: SHASTA-5 Study

We are studying whether plozasiran can help adults with severe hypertriglyceridemia reduce their triglyceride levels and lower the risk of acute pancreatitis. The trial also looks at the treatment's safety and how it affects patients' overall health.

High Triglycerides>2 yearsConfirmation phase (III)6-10 visitsPost-Trial Drug AccessInvestigational MedicinesCost ReimbursementPartially RemoteEndocrinologyGastroenterology

Cefiderocol in Peritoneal Dialysis Patients

We are studying how cefiderocol is processed in the body of patients receiving peritoneal dialysis. This research aims to improve treatment options for infections in these patients.

Patients Undergoing Peritoneal Dialysis>2 yearsSafety phase (I)Infectious DiseasesNephrology

Non-Small Cell Lung Cancer: Drug Sequencing Study

We are investigating the best order to use two medications for patients with advanced non-small cell lung cancer that has specific mutations. This study aims to see which treatment sequence may improve outcomes for these patients.

Non-small Cell Lung Cancer (NSCLC)>2 yearsEfficacy phase (II)No PlaceboStandard MedicinesOncology

Dopamine Changes in Depression: Escitalopram vs. Bupropion

We are studying how rewards affect dopamine levels in the brain of people with major depressive disorder compared to healthy volunteers. This trial also looks at how two different antidepressants may influence these changes.

Major Depression>2 yearsMonitoring phase (IV)11-15 visitsNo PlaceboStandard MedicinesPsychiatry

Zinc Acexamate for Advanced Chronic Liver Disease

We are studying whether Zinc Acexamate can improve health outcomes for patients with advanced chronic liver disease. This trial compares its effects to a placebo to see if it reduces complications and improves survival.

Advanced Chronic Liver Disease>2 yearsConfirmation phase (III)Standard MedicinesHepatologyInternal Medicine

Acute Myeloid Leukemia: NOPHO-DBH AML 2012 Study

We are researching new treatment options for children and adolescents with acute myeloid leukemia. The goal is to find more effective therapies while reducing side effects and improving overall outcomes.

Acute Myeloid Leukemia>2 yearsConfirmation phase (III)No PlaceboStandard MedicinesOncologyPediatrics

Primary Plasma Cell Leukemia: New Treatment with Bortezomib and Daratumumab

We are studying a combination of medications for people with primary plasma cell leukemia to see if it improves treatment outcomes and safety. This trial will help us understand how well this new approach works compared to current treatments.

Plasma Cell Leukemia>2 yearsEfficacy phase (II)>20 visitsNo PlaceboStandard MedicinesHematologyOncology

Crohn’s Disease: Tulisokibart Treatment Study

We are testing a new medication, tulisokibart, for people with moderately to severely active Crohn’s disease. The goal is to see if it helps achieve remission and improve symptoms compared to a placebo.

Crohn's Disease>2 yearsConfirmation phase (III)Post-Trial Drug AccessInvestigational MedicinesCost ReimbursementPartially RemoteGastroenterology

Hepatocellular Carcinoma: IMA970A and Durvalumab

We are testing a new treatment combination for patients with early-stage liver cancer after standard therapies. This study aims to see if it can improve treatment results.

Early Stage Liver Cancer>2 yearsSafety phase (I)HepatologyOncology

Fecal Microbiota Transplantation: KF2022#1 Trial

We are investigating how fecal microbiota transplantation may affect enzyme activities in the body. This study aims to understand its potential benefits for patients with certain health conditions.

Irritable Bowel SyndromeClostridioides difficile Infection>2 yearsSafety phase (I)GastroenterologyInternal Medicine

Transthyretin Amyloidosis with Cardiomyopathy: Vutrisiran Study

We are evaluating the safety and effectiveness of vutrisiran in patients with transthyretin amyloidosis and heart issues. This study includes those continuing treatment or switching from another medication.

Cardiac Amyloidosis>2 yearsConfirmation phase (III)11-15 visitsPost-Trial Drug AccessNo PlaceboInvestigational MedicinesCost ReimbursementCardiologyInternal Medicine

Acute Myeloid Leukemia: L-Annamycin with Cytarabine

We are studying a new treatment combining L-Annamycin with Cytarabine for adults with difficult-to-treat acute myeloid leukemia. The goal is to see if this combination can help achieve remission better than a placebo.

Acute Myeloid Leukemia>2 yearsEfficacy phase (II)Confirmation phase (III)6-10 visitsInvestigational MedicinesCost ReimbursementPartially RemoteOncology

Wiskott-Aldrich Syndrome: Long-term Study of Gene Therapy

We are examining the long-term safety and effectiveness of a gene therapy treatment for individuals with Wiskott-Aldrich Syndrome. This study aims to provide insights into how well the treatment works over time.

Wiskott-Aldrich Syndrome>2 yearsConfirmation phase (III)No PlaceboInvestigational MedicinesPartially RemoteHematologyInfectious Diseases

Siponimod for Progressive Multiple Sclerosis

We are studying how siponimod affects brain lesions and nerve damage in patients with secondary progressive MS. The trial also looks at its impact on cognitive health and long-term safety.

Progressive Multiple Sclerosis>2 yearsMonitoring phase (IV)No PlaceboInvestigational MedicinesNeurology